May 2–4, 2022
Join us and other leading CEOs, top investors, senior Harvard faculty and government leaders to see what’s next in Gene and Cell Therapy. Three unprecedented days highlight what's being discussed and the opportunities that come alongside this translational innovation.
Register today and join us in Boston.
Anne Klibanski, MD
CEO, Mass General Brigham
|
|
|
Laura Aguilar, MD, PhD
Co-founder, Candel
Irina Antonijevic, MD, PhD
CMO & Head of R&D, Triplet
Natalie Artzi, PhD
Assistant Professor, Neurology, BWH
Sarah Boyce
CEO, Avidity Biosciences, Inc.
Shelley Chu, MD, PhD
Partner, Lightspeed Venture Partners
Monica Coenraads
CEO, Rett Syndrome Research Trust
Christina Coughlin, MD, PhD
CEO, Cytoimmune
Merit Cudkowicz, MD
Chair, Neurology, MGH; Julieanne Dorn Professor of Neurology, HMS
Anne Finucane
Meredith Fisher, PhD
Partner, Mass General Brigham Ventures
Alexandria Forbes, PhD
President & CEO, MeiraGTx
Christine Fox
President, Novartis Gene Therapies
Erin Harris
Chief Editor, Cell & Gene
Rachel Haurwitz, PhD
CEO, Caribou
Kristen Hege, MD
SVP, Early Clinical Development, Hematology/Oncology & Cell Therapy, Bristol Myers Squibb
Susan Hockfield, PhD
President Emerita and Professor of Neuroscience, MIT
Staci Kallish, DO
President, Board of Directors, National Tay Sachs and Allied Diseases
Rosana Kapeller, MD, PhD
CEO, ROME
Anne Klibanski, MD
CEO, Mass General Brigham
|
|
Marcela Maus, MD, PhD
Director, Cellular Immunotherapy, Cancer Center, MGH; Associate Professor, HMS
Rachel McMinn, PhD
CEO, Neurogene
Maria Millan, MD
CEO, California Institute for Regenerative Medicine
Sarah Nikiforow, MD, PhD
Technical Director, Immune Effector Cell Therapy Program, Medical Director, Connell and O'Reilly Families Cell Manipulation Core Facility, DFCI; Assistant Professor of Medicine, HMS
Rebecca Oberman, PhD
Executive Director, ML4 Foundation
Arati Rao, MD
SVP, Clinical Development, PACT Pharma
Vicki Sato, PhD
Chairman of the Board, Vir Biotechnology
Christine Seidman, MD
Director, Cardiovascular Genetics Center, BWH; Thomas W. Smith Professor of Medicine and Genetics, HMS
Laura Sepp-Lorenzino, PhD
CSO, Intellia
Christi Shaw
CEO, Kite, a Gilead Company
Angela Shen, MD
Clinical and Translational Market Sector Leader, Mass General Brigham Innovation
Erica Shenoy, MD, PhD
Associate Chief, Infection Control Unit, MGH; Associate Professor, HMS
Susan Slaugenhaupt, PhD
Scientific Director, Mass General Research Institute, MGH; Professor, Neurology, HMS (2022 Co-Chair)
Catherine Stehman-Breen
CEO, Chroma Medicine
Ran Zheng
CEO, Landmark Bio
|
|
May 2–4, 2022 | Gene and Cell Therapy | In-Person
The Forum team will continue to monitor COVID-19 and event safety protocols.
|
|
|
|
|
|
|
